Frontiers in Oncology - Tanja Gruber, MD, PhD

"Establishing Preeminence in Translational Pediatric Oncology: Bass Center Vision 2025," presented by Tanja Gruber, MD, PhD. Dr. Gruber is the Division Chief of Pediatric Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine and Director of the Bass Center for Cancer and Blood Disorders. She is a product of the University of Washington, with dual BS degrees in Biology and Biochemistry; University of Southern California, there with MD in Medicine and PhD in Immunology; and Children’s Hospital of Los Angeles for Internship and Residency in Pediatrics and then Fellowship in Hematology and Oncology. #cancer #leukemia #cancerresearch

Learn more about our Frontiers in Oncology series: https://med.stanford.edu/cancer/train...
Learn more about the Stanford Cancer Institute: https://med.stanford.edu/cancer

Follow the Stanford Cancer Institute
LinkedIn:   / stanford-cancer  
Twitter:   / stanfordcancer  
Subscribe to the Stanford Cancer Institute:    / @stanfordcancerinstitute  
-----------------------------------------------------------------------------------------------------------------------------
0:00 Introduction
0:04 Frontiers in Oncology
2:07 Establishing Preeminence in
2:42 Childhood ALL: The Ultimate Success Store
7:39 Initial Clinical Observation
10:27 Pathogenesis: Recruitment of Transcripti Cofactors that Promote Elongation at Target
11:54 KMT2Ar Infant ALL is Characterized by Low Burden of Mutations
17:50 Bortezomib Depletes H2Bub
21:07 Bortezomib Turns Off the KMT2A Transcriptional Pr and it's Downstream Targets
22:35 Protein Dynamics on a Global Scale
27:53 Mechanism of Bortezomib and Vorinost Activity in KMT2Ar Leukemia
29:08 Total Therapy for Infants ! (TINI)
29:26 Study Objectives
31:58 Outcome Estimates TINI March 2020
33:10 Event Free Survival
37:14 Pediatric Oncology at Stanford
39:21 Striving to Cure the Uncurable: GD2 CART in DIPG
41:34 Continue to Strengthen Foundational Programs and Advance our Differentiate
44:44 How Do We Get There
47:27 Pediatric Hematology Oncology Research
49:15 Key Initiatives Vision 2025
50:23 Conclusions Part II
50:58 Acknowledgements